MatriSys commences dosing in Phase IIa trial for atopic dermatitis

MatriSys Bioscience has started dosing patients with a lotion containing Staphylococcus hominis (S. hominis) in a Phase IIa clinical trial to treat adults with moderate-to-severe atopic dermatitis (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news